Treatment of gonorrhoea by penicillin and a renal blocking agent (probenecid).
D000667:Ampicillin / Q000009:adverse effects / Q000627:therapeutic use; D001315:Australia; D003470:Culture Media; D003875:Drug Eruptions / Q000209:etiology; D004917:Erythromycin / Q000627:therapeutic use; D006069:Gonorrhea / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000652:urine; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects; D008297:Male; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D010118:Oxytetracycline / Q000627:therapeutic use; D010401:Penicillin G Benzathine / Q000627:therapeutic use; D010402:Penicillin G Procaine / Q000097:blood / Q000627:therapeutic use*; D010403:Penicillin Resistance; D011339:Probenecid / Q000627:therapeutic use*; D013307:Streptomycin / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D014526:Urethritis / Q000209:etiology
D003470:Culture Media; D010402:Penicillin G Procaine; D007612:Kanamycin; D004917:Erythromycin; D000667:Ampicillin; D013752:Tetracycline; D011339:Probenecid; D010401:Penicillin G Benzathine; D010118:Oxytetracycline; D013307:Streptomycin